德視佳國際眼科集團(tuán)成功在中國香港上市

德視佳國際眼科有限公司(EuroEyes)是提供視力矯正的主流眼科集團(tuán)之一，已于10月15日成功完成了其股票在香港聯(lián)合交易所有限公司(“香港聯(lián)交所”)主板的上市。全球發(fā)售所得款項(xiàng)總額為5.95億港元(包括超額配股權(quán))。

With an issue price of 7,50 Hong Kong dollars, the first exchange rate was 14,20 Hong Kong dollars, about 90 percent higher.

發(fā)行價(jià)為7.50港元，首次兌換價(jià)為14.20港元，約高90%。

With the proceeds from the IPO, EuroEyes plans above all to build clinics in major Chinese cities such as Chengdu and Chongqing, make possible acquisitions of clinics in Europe and strengthen its marketing activities.

借助首次公開募股的收益，德視佳眼科首先計(jì)劃在成都和重慶等中國主要城市開設(shè)新診所，并加強(qiáng)其市場活動(dòng)。

"In China, there is a huge need for vision correction. According to a market analysis, almost 90 percent of young people are severely nearsighted. We expect 655 million people in 2023. Presbyopia, which is corrected with a trifocal lens, also plays an important role," says Dr. J?rn S. J?rgensen, founder, chairman and CEO of EuroEyes.

“在中國，人們對視力矯正有很大的需求。根據(jù)市場分析，將近90%的年輕人是近視眼。我們預(yù)計(jì)2023年將有6.55億人。隨著中國人口的日益老齡化，用三焦點(diǎn)晶體矯正中老年人的老花眼也將扮演重要的角色來幫助到中國人民”，德視佳眼科創(chuàng)始人，董事長兼首席執(zhí)行官約根森博士說道。

The Group has established itself as a high-end provider of surgical vision correction in China. "Our unique selling points include the excellent reputation of German ophthalmology, the large number of operations performed, the early use of modern technologies, the quality and comfort of services, customer satisfaction and the outstanding location of the clinics in the major cities," says Dr. J?rgensen.

德視佳眼科集團(tuán)已經(jīng)成為中國視力矯正的高端集團(tuán)。“我們獨(dú)特的特點(diǎn)包括德國眼科手術(shù)的卓越聲譽(yù)、大量的手術(shù)量、最早使用的現(xiàn)代眼科技術(shù)、服務(wù)的質(zhì)量和舒適性、客戶滿意度以及主要城市診所的優(yōu)越地理位置。”約根森博士介紹道。

"We have chosen Hong Kong as our stock exchange location because our future growth is mainly in China and we can finance our expansion from the IPO," says Dr. Markus Braun, CFO of EuroEyes.

德視佳EuroEyes的首席財(cái)務(wù)官M(fèi)arkus Braun博士說：“我們之所以選擇中國香港作為我們的證券交易所在地，是因?yàn)槲覀兊奈磥碓鲩L主要集中在中國，我們可以通過IPO籌集資金。”

In the initial public offering, 79,334,000 offer shares were issued by EuroEyes, of which 71,400,000 offer shares were for its international private placement to professional investors and the remaining 7,934,000 shares were for its Hong Kong public offering. Trading of the EuroEyes share on the SEHK started on 15 October 2019. The public offering in Hong Kong started on 30 September 2019 and finished on 8 October 2019. The offer price and the final allocation were announced on 14 October 2019.

在首次公開募股中，德視佳EuroEyes發(fā)行了79,334,000股的發(fā)行股份。其中71,400,000股發(fā)行是針對專業(yè)投資者的國際私募發(fā)行，其余7,934,000股則是其在香港的公開發(fā)行。德視佳EuroEyes的股份于2019年10月15日開始在聯(lián)交所買賣。香港公開發(fā)售于2019年9月30日開始，并于2019年10月8日完成。報(bào)價(jià)和最終分配于2019年10月14日宣布。

BOCI Asia Limited acted as global coordinator for the listing. BOCI Asia Limited, China Securities (International) Corporate Finance Company Limited and Fosun Hani Securities Limited acted jointly as bookrunners and lead managers. Eversheds Sutherland was the Hong Kong and German legal adviser to EuroEyes in its listing.

中銀國際亞洲有限公司擔(dān)任上市的全球協(xié)調(diào)人。中銀國際亞洲有限公司，中國證券(國際)企業(yè)融資有限公司和復(fù)星證券有限公司共同擔(dān)任賬簿管理人和牽頭經(jīng)辦人。Eversheds Sutherland是德視佳EuroEyes上市的中國香港和德國法律顧問。

EuroEyes International Eye Clinic Limited is a Cayman Islands incorporated company with significant business in Denmark, Germany and China. In terms of sales, the company ranks first in the market for modern refractive laser and lens surgery (excluding PRK and LASEK) in Germany and second in Denmark. The Group was the first foreign provider of surgical vision correction in the People's Republic of China (besides those from Hong Kong, Macau and Taiwan). EuroEyes has a total of 15 locations in Germany, including its headquarters in Hamburg, 6 locations in China, including Shanghai and Beijing, and a further 5 locations in Denmark.

德視佳國際眼科集團(tuán)是一家在開曼群島注冊成立的公司。在丹麥，德國和中國擁有重要業(yè)務(wù)。就銷售而言，德視佳眼科在現(xiàn)代屈光激光和晶狀體手術(shù)(不包括PRK和LASEK)市場上在德國排名第一，在丹麥排名第二。該集團(tuán)是中華人民共和國(除中國香港，中國澳門和中國臺(tái)灣地區(qū))首家外國眼科手術(shù)視力矯正的德國集團(tuán)。德視佳眼科EuroEyes在德國共有15個(gè)診所，包括其在德國漢堡的總部;在中國的6個(gè)診所，包括上海、北京、廣州、深圳和杭州;以及在丹麥的5個(gè)診所。

Legal Notice

This information does not constitute a public offering of shares in Germany or Denmark or within any other country of the European Monetary Area ("EEA") or outside Hong Kong.

法律聲明

該信息不在德國、丹麥或歐洲貨幣區(qū)(“EEA”)的任何其他國家或中國香港以外的地區(qū)公開發(fā)行股票。

生成海報(bào)

免責(zé)聲明：本網(wǎng)站內(nèi)容主要來自原創(chuàng)、合作伙伴供稿和第三方自媒體作者投稿，凡在本網(wǎng)站出現(xiàn)的信息，均僅供參考。本網(wǎng)站將盡力確保所提供信息的準(zhǔn)確性及可靠性，但不保證有關(guān)資料的準(zhǔn)確性及可靠性，讀者在使用前請進(jìn)一步核實(shí)，并對任何自主決定的行為負(fù)責(zé)。本網(wǎng)站對有關(guān)資料所引致的錯(cuò)誤、不確或遺漏，概不負(fù)任何法律責(zé)任。任何單位或個(gè)人認(rèn)為本網(wǎng)站中的網(wǎng)頁或鏈接內(nèi)容可能涉嫌侵犯其知識(shí)產(chǎn)權(quán)或存在不實(shí)內(nèi)容時(shí)，應(yīng)及時(shí)向本網(wǎng)站提出書面權(quán)利通知或不實(shí)情況說明，并提供身份證明、權(quán)屬證明及詳細(xì)侵權(quán)或不實(shí)情況證明。本網(wǎng)站在收到上述法律文件后，將會(huì)依法盡快聯(lián)系相關(guān)文章源頭核實(shí)，溝通刪除相關(guān)內(nèi)容或斷開相關(guān)鏈接。